No Picture
Trading Ideas

Elon Musk unveils Tesla’s new Cybertruck

Elon Musk unveiled Tesla’s new Cybertruck at the Los Angeles Auto Show. The Tesla CEO ran several tests at the show to demonstrate the strength of the car’s body and the glass. Yahoo Finance’s Dan Roberts, Heidi Chung, Kristin Myers and Melody Hahm discuss on YFi AM. …read more […]

No Picture
Trading Ideas

3 “Strong Buy” Stocks Set for Triple Digit Gains

Which names can step up to the plate and hit the ball right out of the park? We are referring to the stocks that have a long growth runway ahead of them, lining up to deliver a win in the long-run. While these kinds of investments are highly sought after, it doesn’t mean they are easy to find.Luckily, TipRanks’ Stock Screener can help get the job done. The tool enabled us to filter our search by analyst consensus, price target and market cap as well as sort the results by upside potential from the current share price. As a result, …read more […]

No Picture
Trading Ideas

Victoria’s Secret Fashion Show cancelled this year

After more than a two decade run, the Victoria Secret Fashion Show is bidding farewell. Many have been predicting the Fashion Show’s downfall especially as the company continues to receive widespread criticism for its non-inclusive campaigns. Yahoo Finance’s Dan Roberts, Heidi Chung and Kristin Myers discuss on YFi AM. …read more […]

No Picture
Business News

Take Five: A spanner in the global economic works

Can we have it both ways? For two decades, trade expansion has fueled rapid global economic growth. But with trade volumes contracting at a rate of more than 1% year-on-year and the Sino-U.S trade war nearing its two-year anniversary, world growth will plumb decade-lows next year, the Organisation for Economic Co-Operation and Development predicts.

…read more […]

No Picture
Trading Ideas

AstraZeneca shares rise on early U.S. approval for leukemia drug

AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie . AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go ahead for the company’s Calquence drug to treat chronic lymphocytic leukemia (CLL), one of the most common types of leukemia in adults. …read more […]